| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. | Chief Commercial Officer | Common Stock | 109K | $249K | $2.28 | Jun 30, 2021 | Direct |
| BioXcel Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 19K | $10.5K | $0.55 | Oct 3, 2024 | Direct |
| BioXcel Therapeutics, Inc. | Chief Commercial Officer | Restricted Stock Units | 7.5K | $9.6K | $1.28 | Sep 15, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics, Inc. | Sep 17, 2024 | 2 | -$3.45K | 4 | Oct 3, 2024 | Chief Commercial Officer |
| BTAI | BioXcel Therapeutics, Inc. | Sep 15, 2024 | 3 | -$149 | 4 | Sep 17, 2024 | Chief Commercial Officer |
| BTAI | BioXcel Therapeutics, Inc. | Jun 15, 2024 | 1 | $0 | 4/A | Sep 17, 2024 | Chief Commercial Officer |
| BTAI | BioXcel Therapeutics, Inc. | Mar 15, 2024 | 3 | -$2.66K | 4 | Apr 8, 2024 | CHIEF COMMERCIAL OFFICER |
| BTAI | BioXcel Therapeutics, Inc. | Mar 15, 2023 | 2 | $0 | 4 | Mar 16, 2023 | CHIEF COMMERCIAL OFFICER |
| BTAI | BioXcel Therapeutics, Inc. | Jan 17, 2022 | 1 | $0 | 4 | Jan 19, 2022 | CHIEF COMMERCIAL OFFICER |
| BTAI | BioXcel Therapeutics, Inc. | Jan 17, 2022 | 0 | $0 | 3 | Jan 19, 2022 | CHIEF COMMERCIAL OFFICER |
| VYNE | VYNE Therapeutics Inc. | Jun 30, 2021 | 1 | -$18.1K | 4 | Jul 2, 2021 | Chief Commercial Officer |